RARE
Ultragenyx Pharmaceutical Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 477.97K | $7.18M | +1 | −1 |
| Q2 2026 | 97 | -6 | 59.88M | $1.99B | +8 | −14 |
| Q1 2026 | 106 | +4 | 55.54M | $1.16B | +10 | −7 |
| Q4 2025 | 102 | 0 | 62.50M | $1.44B | +1 | n/a |
| Q3 2025 | 19 | -1 | 45.29M | $1.36B | n/a | −2 |
| Q2 2025 | 18 | -1 | 33.50M | $1.22B | n/a | −1 |
| Q1 2025 | 16 | 0 | 17.22M | $623.52M | n/a | n/a |
| Q4 2024 | 16 | +1 | 16.41M | $690.18M | +1 | n/a |
| Q3 2024 | 14 | +2 | 15.84M | $879.45M | +2 | n/a |
| Q2 2024 | 12 | n/a | 15.75M | $647.24M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 4.56M | n/a | $187.26M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 2 | T. Rowe Price ✦ | 2.99M | n/a | $122.97M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Millennium Management ✦ | 1.85M | n/a | $76.07M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.51M | n/a | $61.89M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 1.13M | n/a | $46.57M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 1.12M | n/a | $46.24M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 1.00M | n/a | $41.20M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 568.31K | n/a | $23.36M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Point72 Asset Management ✦ | 539.75K | n/a | $22.18M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 203.44K | n/a | $8.36M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Citadel Advisors ✦ | 173.95K | n/a | $7.15M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | AQR Capital Management ✦ | 97.10K | n/a | $3.99M | 0.0% | n/c | 1 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 293 holders, 97.86M shares, $1.96B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 7.07K sh · $107,898
Officer · 1.28K sh · $17,410
Officer · 161 sh · $2,252
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology